国内“诺和泰+诺和忻+诺和盈”一季度卖了“3.18亿美元”

生物科技馆
May 08, 2025

2025年5月7日,诺和诺德对外公布2025年Q1业绩,公司总营收约合110.1亿美元,同比增长18%;美国市场收入约合62.49亿美元,同比增长53%;中国市场收入约合7.92亿美元,同比增长9%。据悉,诺和诺德一季度,“减重注射版”-Wegovy®销售额约合24.48亿美元,同比增长67%;“降糖口服版”-Rybelsus®销售额约合8.03亿美元,同比增长6%;“降糖注射版”Ozempic®...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10